6917 Stock Overview
Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Andros Pharmaceuticals Co.,Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$21.70 |
52 Week High | NT$39.60 |
52 Week Low | NT$19.80 |
Beta | 0 |
1 Month Change | -1.81% |
3 Month Change | 6.63% |
1 Year Change | -38.79% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -32.19% |
Recent News & Updates
Recent updates
Shareholder Returns
6917 | TW Pharmaceuticals | TW Market | |
---|---|---|---|
7D | 1.2% | -0.3% | 1.1% |
1Y | -38.8% | 2.2% | 28.2% |
Return vs Industry: 6917 underperformed the TW Pharmaceuticals industry which returned 2.2% over the past year.
Return vs Market: 6917 underperformed the TW Market which returned 28.2% over the past year.
Price Volatility
6917 volatility | |
---|---|
6917 Average Weekly Movement | 6.4% |
Pharmaceuticals Industry Average Movement | 3.9% |
Market Average Movement | 4.9% |
10% most volatile stocks in TW Market | 8.8% |
10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 6917 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6917's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | n/a | n/a | www.andros.com.tw |
Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies. The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anesthetic that is in Phase I/II clinical trial for treatment of Osteoarthritis; and siRNA, an anti-sense oligonucleotide and DNA candidate. Its preclinical phase products are APC310 and APC501 for anesthesia to intravenous catheter placement and venipuncture; and APC401, a special emulsified solution for anesthesia of post-surgery pain.
Andros Pharmaceuticals Co.,Ltd Fundamentals Summary
6917 fundamental statistics | |
---|---|
Market cap | NT$754.55m |
Earnings (TTM) | NT$0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 6917 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6917 income statement (TTM) | |
---|---|
Revenue | NT$0 |
Cost of Revenue | NT$0 |
Gross Profit | NT$0 |
Other Expenses | NT$0 |
Earnings | NT$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did 6917 perform over the long term?
See historical performance and comparison